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Influence of continuous ambulatory peritoneal dialysis on the anemia of
endstage renal disease. Ta evaluate the effect of Continuous ambulatory
peritoneal dialysis (CAPD) on the anemia of endstage renal disease,
serial measurements of red cell mass and other hematological parame-
ters were performed in 34 patients. Twenty-five patients were measured
at the start and at 6 months (group 1), 13 at the start, at 6 and 12 months
(group 2), and 11 were followed during their second year of treatment
with measurements at 12, 18, and 24 months (group 3). In group 1 the
hematocrit rose from 24.6 0.9 to 29.9 0.8% (P < 0.01). The red cell
mass increased from 879 44 to 1019 47 ml (P < 0.01). The
calculated plasma volume decreased from 2915 174 to 2568 136 ml
(P < 0.01). In group 2 at 6 months the hematocrit rose from 24.7 1.2
to 30.7 1.0% (P <0.01); the red cell mass increased from 924 66 to
1059 71 ml (P < 0.05). The calculated plasma volume decreased at 6
months from 3001 201 to 2555 170 ml (P < 0.01). No significant
changes occurred between 6 and 12 months. In group 3 no significant
changes in hematocrit, red cell mass, or plasma volume were observed.
It is concluded that the rise in hematocrit in CAPD patients is due to an
increase in red cell mass and also to a decrease in plasma volume. These
changes are manifest within 6 months of treatment. The rise in red cell
mass represents an improvement in renal anemia in these patients.
Influence de Ia dialyse péritonéale continue ambulatoire sur l'anémie
rénale. Afin d'évaluer l'effet de Ia dialyse péritonéale continue ambula-
toire sur l'anémie rénale, nous avons étudié Ic volume globulaire et
d'autres paramétres hématologiques chez 34 malades. Les mesures ont
été faites au debut et après 6 mois de traitement chez 25 malades
(groupe I) et après 6 et 12 mois de traitement chez 13 malades (groupe
2), et onze malades ont été examines pendant leur deuxième année de
traitement avec des mesures après 12, 18, et 24 mois (groupe 3). Dans Ic
groupe I l'hématocrite augmenta de 24.6 0.9 a 29.9 0.8% (P <
0.01). Le volume globulaire augmenta de 879 44 a 1019 47 ml (P <
0.01). Le volume plasmatique calculé diminua de 2915 174 a 2568
136 ml (P < 0.01). Dans Ic groupe 2 une augmentation de l'hCmatocrite
fut observée après 6 mois, de 24.7 1.2 a 30.7 1.0% (P < 0.01); Ic
volume globulaire augmenta de 924 66 a 1059 71 ml (P < 0.05). Le
volume plasmatique calculC diminua de 3001 201 a 2555 170 ml (P
< 0.01). Aucun changement ne fut observe dans cc groupe entre les
valeurs obtenues après 6 et 12 mois. Dans Ic groupe 3 aucun change-
ment ne fut observe dans l'hCmatocrite, Ic volume globulaire. ou Ic
volume plasmatique. Cette étude dCmontre que l'élévation de l'hCmato-
crite chez les malades en DPCA est due et a unc augmentation du
volume globulaire et a une diminution du volume plasmatique, surven-
ant dans les premiers 6 mois du traitement. L'élévation du volume
globulaire dCmontre une amelioration réelle de l'anCmie daus ces
malades.
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An early rise in hematocrit readings, hemoglobin concentra-
tions, and erythrocyte counts has been observed in patients
treated with continuous ambulatory peritoneal dialysis (CAPD)
[1, 21.
These higher values could be interpreted as a better correc-
tion for anemia in CAPD patients when compared to the results
obtained in hemodialysis. However, it is evident that all the
usually determined parameters to assess the degree of anemia in
dialyzed patients are influenced by changes in red cell mass as
well as in plasma volume. The relatively high incidence of both
orthostatic hypotension and symptoms of volume depletion in
CAPD patients [3] suggests that the plasma volume can be
influenced by CAPD treatment. As far as we know, a systemat-
ic and prospective study of changes in red cell mass and plasma
volume has not yet been reported in CAPD.
In view of the substantial interindividual variability in these
parameters, the present study reports paired observations of
the evolution of hematocrit, red cell mass, and plasma volume
in 34 selected patients treated with CAPD over a 2-year period.
Methods
Studies were performed in a total of 34 selected CAPD
patients. Informed consent was obtained from the patients prior
to the study. Not included in the study were patients suffering
from systemic diseases, except for diabetes mellitus, patients
with appreciable chronic blood loss or having received blood
transfusions within 3 months prior to the study. Patients with
more than three episodes of peritonitis in 6 months were also
excluded.
The daily protein intake, estimated from the measurement of
urea nitrogen appearance [41, ranged in these patients from 0.9
to 1.5 g/kg body weight. None of them received oral iron or
vitamin supplements. No blood transfusions were performed
during the study. Determinations of serum levels of vitamin B12
and folic acid, at the start of CAPD and at regular intervals
thereafter, revealed results within the normal range.
The patients studied (20 females, 14 males) include 5 with
chronic glomerulonephritis, 16 with chronic pyelointerstitial
nephritis, 3 with nephroangiosclerosis, 3 with polycystic kidney
disease, I with reflux nephropathy, I with Alport syndrome, I
with diabetic nephropathy, I with thromboembolic kidney
disease, and 3 with unknown endstage renal disease.
Their ages ranged from 35 to 77 years (mean age, 57.9 years).
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months in the patients of group 1. Similar stable values were
obtained in the patients of group 3 at 24 months of CAPD (mean
blood urea: 1.23 0.12 g/liter and mean serum creatinine: 9.6
0.6 mg%). Serum electrolytes and acid-base parameters re-
mained within the normal range.
Statistical analysis was performed with the Wilcoxon
matched pairs, signed ranks test, the Friedman two-way analy-
sis of variance (Anova) and the Fisher exact test (FET).
Statistical significance was accepted at P < 0.05 level. Values
are expressed as the means SEM.
Results
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Fig. 1. Relationship between measured (1311 albumin) and calculated
(SSmTc labelled autologous red blood cells) plasma volume in CAPD
patients (N = 44; r = 0.94).
The residual renal function (endogenous creatinine clearance)
varied between 0 and 6.2 ml/min (mean, 2.8 0.3 mI/mm).
None of the patients were anephric, but seven were anuric.
The patients were divided into three groups. Group 1 (N =
25) was studied at the start and after 6 months of CAPD. Group
2 was composed of 13 patients of group 1, but where an
additional determination of red cell mass after 12 months of
CAPD was performed. Group 3 consisted of nine patients who
were on CAPD for more than 1 year and where determinations
were performed at 12, 18, and 24 months. These patients were
not studied during their first year on CAPD. In addition, in two
patients from group 2, a follow-up study in the second year was
performed, and these results were therefore included in group
3.
Standard hematologic determinations were performed in ev-
ery patient. The hematocrit (Hct) was measured on venous
blood samples with the macromethod of Wintrobe. A correction
factor of 0.96 for trapped plasma was applied, but no correction
for total body hematocrit was made. Red cell mass was mea-
sured by volume dilution of 99 Tc labelled autologous red
blood cells [5], and the plasma volume was calculated from the
red cell mass and venous hematocrit.
In addition, in a separate study, red cell mass and plasma
volume were measured simultaneously in 44 CAPD patients
with 99 Tc red blood cells and with ''i labelled albumin [5],
respectively. As can be noted from Figure 1, an excellent
correlation between the directly measured plasma volume
(albumin method) and the calculated values was obtained (r =
0.94; P < 0.001). However, the indirect method underestimates
the absolute values for plasma volume with about 20%, when
compared to the values, measured by the albumin method (2604
102 ml versus 3235 113 ml).
Additional parameters, such as serum PTH levels and ferritin
concentrations, were measured over the same time interval by
radioimmunologicai techniques.
CAPD was carried out with four daily exchanges of a 2-liter
dialysate (Dianeal®, Travenol Laboratories, Deerfield, Illinois).
The blood urea and serum creatinine levels stabilized at values
of 1.18 0.06 g/liter and 9.45 0.4 mg%, respectively, at 6
The individual data, hematocrit, red cell mass, plasma vol-
ume, ferritin, PTH, residual creatinine clearance, and mean
corpuscular volume (MVC) for groups 1 and 2 are given in
Table 1.
Group 1 (0 to 6 months). A significant increase both in
hematocrit from 24.6 0.9 to 29.9 0.8% (P <0.01) and red
cell mass from 879 44 to 1019 47 ml (P < 0.01) is noted at
6 months. The calculated plasma volume however decreased in
the same period from 2915 174 to 2568 136 ml (P < 0.01).
The red cell mass expressed in milliliters per kilograms of
body weight was 14.9 0.6 at the start and increased to 16.5
0.7 ml/kg after 6 months of CAPD (P < 0.01). The correspond-
ing values for plasma volume were 47.1 1.9 ml/kg and 40.8
1.4 mi/kg, respectively (P < 0.01).
Therefore, it can be concluded that the increase in hematocrit
observed over the first 6 months of CAPD can be explained by
both an increase in red cell mass and a decrease in plasma
volume.
Group 2 (0 to 6 and 12 months). Significant differences in the
results of the three periods for hematocrit, red cell mass, and
plasma volume were observed (Anova, P < 0.005). Further
analysis by the Wilcoxon test showed similar results as in group
1 at 6 months. There was a significant increase in both hemato-
crit from 24.7 1.2 to 30.7 1.2% (P < 0.01) and red cell mass
from 924 66 (14.7 0.9 mI/kg) to 1059 71 ml (17.2 1.1
ml/kg), (P <0.05). The plasma volume decreased from 3001
201 (48.5 2.6 mllkg) to 2555 170 ml (41.0 2.0 mllkg), (P <
0.01). No further significant changes in hematocrit, red cell
mass, and plasma volume occurred between 6 and 12 months.
The mean corpuscular volume (MCV) at the start was normal
in all patients except one (patient no. 25) and remained within
the normal range during the study except in patients 4 and 13
(Table 1). Serum ferritin levels were normal in all patients at the
start and decreased at 6 months both in group 1 from 303 36 to
247 37 ng/ml (P < 0.02) and group 2 from 291 49 to 196 46
ng/ml (P < 0.01).
No consistent changes in serum PTH occurred. Any relation-
ship between evolution in serum PTH levels and changes in red
cell mass could not be demonstrated (FET P > 0.2).
Three of the four anuric patients in groups I and 2 showed an
increase in red cell mass. Among the five patients previously
treated by hemodialysis, three responded to CAPD with an
increase in red cell mass.
Group 3 (12 to 18 and 24 months). No significant differences
in the results of the three periods were obtained. The mean
hematocrit in these 11 patients was 34.4 2.2, 35.2 2.1, and
35.5 2.1%; the mean red cell mass was 1150 141, 1130
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Plasma volume, ml MCVa, Ferritinh, ng/ml PTI-1c, mU/mi mm
S 6 12 S 6 12 S 6 12 S 6 12 S
Group 2 (13 to 25)
Mean 24.7 30.7k 31.Ot
SEM ÷1.2 --1.2
924 1059d 1097d 3001 2555k 2633 89 89
÷71 69 89 291 l96 184d 36.3 22.8 24.7 2.812.5 ÷6.8 ÷.6
Abbreviations: MCV, mean corpuscular volume; S, start. Normal range: a 82 to 105 10 to 300 ng/ml: c <6 mU/mI.
P < 0.05.
P < 0.02.
P < 0.01 vs. start value.
A patient previously treated with hemodialysis.
145, 2129 145, and 2209 154 ml, respectively. Expressed
as milliliters per kilogram of body weight, these results were
18.5 1.5, 18.2 2.5, and 18.7 1.9 for red cell mass and 37.1
2.7, 35.4 1.6, and 36.2 2.4 for plasma volume. All other
parameters (MCV, serum ferritin, and serum PTH) remained
unchanged.
Discussion
The major objective of this study was to evaluate the influ-
ence of CAPD on renal anemia in 34 patients, some of them
treated for as long as 2 years. Therefore, it was necessary to
include measurements of red cell mass because the routine
hematological parameters are influenced by changes in plasma
volume.
It could be criticized that in this study the assessment of one
important parameter, plasma volume, was not based on direct
measurements but was derived from the measured red cell
mass. However, we made a comparison in 44 CAPD patients
between this indirect estimation and the plasma volume mea-
sured with 31j labelled albumin. An excellent correlation
between these two methods was obtained. Although the calcu-
lated values were underestimated with approximately 20%
compared to the measured values, this was largely due to the
use of the peripheral venous and not the total body hematocrit
in the calculations.
In the patients where both methods were applied, a mean
total body hematocrit of 24.7 0.7% compared to a mean
venous hematocrit of 29.0 0.9% was found; this gives a ratio
of 0.85. The total body hematocrit was calculated by standard
formulae [5]. When corrected for total body hematocrit, the
mean calculated plasma volume, was 3252 126 ml, compara-
ble to the measured plasma volume of 3235 113 ml in those 44
determinations hus, despite this underestimation of the abso-
lute values, it was felt that the decrease in plasma volume
observed in this study reflects true changes in this parameter.
The most striking observation of this study is that the early
rise of hematocrit in CAPD patients is due to a combination of
an increase in red cell mass, thus a "true" improvement of
1' 22.8 29.5 728 982 2721 2485 83 85 500 500 20.9 20.1 0
2 23.0 29.5 1250 1403 4413 3551 82 90 387 216 4.3 7.8 3.8
3 22.0 26.0 505 610 1901 1833 91 89 537 500 17.0 22.4 5.0
4 25.5 33.0 864 1131 2664 2439 94 79 20 16 9.6 9.6 2.7
5 17.0 22.6 1009 1208 5175 4283 90 89 400 434 17.0 27.0 1.0
6 20.5 28.7 798 1114 3258 2936 95 88 380 479 13.3 15.0 0.9
7 26.0 32.0 844 922 2532 2083 82 88 500 500 6.0 8.8 6.2
8 21.0 24.0 757 958 2993 3200 100 99 267 128 19.4 16.3 2.7
9 21.0 31.0 549 812 2212 1917 88 86 96 220 17.7 12.8 5.5
10 28.5 31.0 827 923 2179 2177 91 91 42 25 64.2 47.0 4.1
11 35.0 36.0 940 884 1858 1671 87 89 163 127 — 43.4 5.0
12' 32.5 25.0 898 762 1952 2415 89 100 500 500 40.0 32.0 0
13 26.5 31.0 36.0 737 642 712 2162 1514 1345 85 90 78 341 71 113 21.0 28.0 31.0 1.0
14 25.5 35.5 33.1 1196 1386 1239 3688 2682 2658 90 89 89 153 61 98 43.0 24.0 35.5 1.9
15g 28.0 30.2 27.0 918 1111 929 2497 2748 2655 86 86 92 500 374 394 157.0 — 106.0 5.0
16 34.5 31.0 27.0 1356 876 1087 2767 2069 3108 89 89 92 200 138 — 9.4 12.2 17.2 5.0
17 29.0 30.0 36.0 1265 1338 1532 3284 3307 2915 85 84 85 363 404 94 14.0 14.0 5.1 3.5
18 24.5 30.0 25.0 1010 1097 918 3285 2710 2906 89 88 89 54 50 175 16.4 14.8 11.2 5.0
l9 20.8 30.0 30.0 708 1004 945 2834 2481 2335 100 89 94 500 324 —. 14.0 17.9 — 0
20 26.2 34.5 38.0 678 894 1019 2019 1804 1773 92 101 93 270 311 510 21.0 9.4 9.0 5.2
21 22.0 37.0 34.0 793 1138 1032 2961 2067 2240 95 87 86 291 43 23 16.0 17.9 14.5 1.0
22' 25.0 35.4 28.5 973 1382 1218 3079 2683 3235 99 94 94 533 500 500 111.0 81.4 24.4 0
23 21.0 25.0 28.0 681 838 925 2696 2653 2513 85 86 86 — 185 59 17.0 — 14.3 4.7
24 20.0 22.0 30.5 676 706 1120 2848 2639 2706 86 87 97 264 56 41 20.2 8.7 16.1 1.1
25 18.0 27.0 30.5 1022 1351 1589 4891 3860 3839 81 82 82 20 20 18 11.4 — 11.6 3.6
Group 1 (Ito 25)
Mean 24.6 29.9k 879 1019 2915 2568 89 89 303 247' 29.2 22.3 3.0
SEM 44 ÷47 --174 ÷1 3.6 ±4
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renal anemia and a decrease in plasma volume. It is obvious
that individual changes in the routine hematological parameters
in patients with CAPD, as with hemodialysis, should be inter-
preted with caution. Divergent changes in hematocrit and red
cell mass can be noted. In patient 13 (Table 1), the increase in
hematocrit was not associated with a rise in red cell mass but
was due to a considerable decrease in plasma volume. On the
other hand, a decrease in hematocrit between 6 and 12 months
together with an increase in red cell mass was observed in
patient 16 (Table 1).
It is important, however, to note that of the 25 patients
studied over 6 and/or 12 months, only six patients (11, 12, 13,
15, 16, and 18) did not experience a rise in red cell mass. Why
these patients did not respond is unclear. There was no differ-
ence in etiology of their renal disease, renal residual function,
or serum PTH levels (Table I). They presented also with similar
stable blood urea and serum creatinine levels as the other
patients, and there was no reason to accept that they were less
adequately dialyzed. Deficiency in folate, vitamin B12, or iron
was ruled out as a factor. Bleeding of any cause was not
apparent.
Several mechanisms are known to play a role in the anemia of
chronic renal failure and one can only speculate why, in
general, improvement of the renal anemia is observed during
CAPD. Although a rise in hematocrit has been noted in patients
given adequate hemodialysis [61, this rise is usually less dramat-
ic than observed in patients on CAPD. To our knowledge, a
systematic study of red cell mass and plasma volume before and
during hemodialysis treatment, has not yet been performed. It
is therefore difficult to exclude that the apparently smaller rise
in hematocrit in the first months of hemodialysis is mainly due
to a less important fall in plasma volume.
Bell et al [71 studied red cell mass among other parameters in
55 patients who were hemodialyzed for a mean period of 4
years. Although a direct comparison with our results is difficult
to make, it is worthwhile to note that the mean value for red cell
mass of 14.9 mI/kg body weight obtained by these authors is
lower than the results obtained in the CAPD patients followed
for 2 years. Furthermore, many hemodialysis patients need
frequent transfusions or are treated with androgens. The latter
treatment is associated with a high level of patient intolerance
[81, and the opinions on their benefit remain controversial [9].
In any case, in our experience, the need for transfusions or
androgen therapy is virtually absent in CAPD patients, in
contrast with observations made in hemodialysis patients. It is
also worthy of note that of the five patients previously treated
with hemodialysis three showed an increase in red cell mass
(Table 1).
Although at the start of CAPD, the arterial P02 has been
reported to decrease, no decrease in P02 was found after 6
months of treatment [101. The early decrease in P02 could
explain an increase of red cell mass in the first months of the
treatment but not a sustained increase over 2 years.
The role of erythropoietin in CAPD is still controversial and
has been investigated in a very limited number of patients [11,
121.
Whereas Lamperi et a! [111 could not find a correlation
between the increase in hematocrit and changes in serum
erythropoietin levels, Zappacosta, Caro, and Erslev [12] ob-
served that only patients with high erythropoietin levels under
CAPD could normalize their hematocrit. It should be noted that
in the latter study, three out of the four responders of a total of
nine patients suffered from polycystic kidney disease.
In the last few years, erythropoiesis-inhibiting factors in sera
of patients with anemia of chronic renal failure have been
described. Recently, Radtke et al [13] provided evidence that
the major endogenous mammalian polyamines, spermine and
spermidine, may be responsible for the inhibition of erythropoi-
esis of uremia. These polyamines are removable from the sera
of azotemic patients by both in vivo and in vitro dialysis. These
compounds have a low molecular weight of around 200 daltons.
It is difficult to explain the improvement of anemia in CAPD
by greater removal of these low molecular substances alone,
since the clearance of small molecules is inferior to hemodialy-
sis, and CAPD is known to induce a better removal of middle
molecular substances [14]. Whether or not middle molecules act
as inhibitors of erythropoiesis is still unclear. Furthermore,
there is now good evidence that some of these substances
probably have molecular weights of 370 to 700 daltons, far
below their previously assumed size [15].
The foregoing explanations do not discount the possibility
that other factors such as less extracorporeal blood loss and
improvement of hemolysis, due to the absence of extracorpore-
al circulation are also playing a role in the better control of the
anemia in CAPD patients.
In summary, the present studies show that CAPD results in
an early improvement of the uremic anemia, as demonstrated
by a significant increase in red cell mass. However, the changes
in routine hematological parameters are also profoundly influ-
enced by an important decrease in circulating plasma volume
occurring with this form of therapy.
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